Filing Flows › 8-K events › Stem
Stem: notice of delisting or failure to meet a listing standard
Form 8-K filed Oct 23, 2026 · items 3.01
Delisting noticesStem Announces Notification of Noncompliance with NYSE Continued Listing Standards
What the filing says
On October 19, 2026, Stem, Inc. (the “Company”) notified the New York Stock Exchange (the “NYSE”) that the Company is not in compliance with the requirement of Section 802.01B of the NYSE Listed Company Manual (“NYSE Manual”) that the Company have an average market capitalization of not less than $50.0 million over a c
ScaleThe filing names $50.0M: about 37% of Stem's annual revenue ($134.6M, four times the latest quarter).
Read the filing on SEC EDGAR →
What usually followsAcross 492 8-Ks reporting Item 3.01 (delisting notice or listing-rule failure) in our universe, the stock's median move the next session was 0.0% (typical size ±2.1%, up 46% of the time); over the following 21 sessions, −0.2%. Every item ranked →
What this kind of filing means
Item 3.01 — Notice of delisting or failure to meet a listing standard. A delisting notice starts a compliance window; companies often answer with a reverse split, a plan, or a move to another market.
Stem at a glance
Stem, Q2 2026: revenue $33.7M (-12% year over year), operating margin -22.8%. The chart follows the revenue to costs, profit and cash.
Stem: every quarter, Q/Q and Y/Y, holders and guidance →
Other recent delisting notices
- Barfresh Food Group Nov 6, 2026
- Fifth Era Acquisition Corp I Nov 6, 2026
- Tempest Therapeutics Nov 6, 2026
- Roku Nov 6, 2026
- Bowman Consulting Group Nov 6, 2026
- Knightscope Nov 6, 2026
- Curis Nov 6, 2026
- Intrusion Nov 5, 2026
- Karyopharm Therapeutics Nov 5, 2026
- Cognition Therapeutics Nov 5, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.